Pap cytopathology and the presence of high-risk human papillomavirus in SurePath liquid preservative and Digene cervical sampler specimens.
The Digene Hybrid Capture 2 (HC2) assay for high-risk human papillomavirus (HPV) identified 92 (28.7%) infected women by testing 320 SurePath liquid-based Pap samples and a hybrid capture 2 (HC2) sampler collection. HPV positivity was predictive for high-grade lesions. A majority of women had normal cervical readings although 15.8% were HPV-positive. Half of the patients with a reading of atypical squamous cells of undetermined significance (ASCUS) (n=16) were HPV-positive.
Kapala
Julius
J
Gamma-Dynacare Medical Laboratories, Brampton, Ont., Canada.
Jang
Dan
D
Patel
Jay
J
Biers
Kathleen
K
Smieja
Marek
M
Chernesky
Max
M
D000293:Adolescent; D000328:Adult; D002294:Carcinoma, Squamous Cell / Q000453:epidemiology* / Q000473:pathology / Q000821:virology; D002584:Cervix Uteri / Q000473:pathology / Q000821:virology; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D006801:Humans; D008875:Middle Aged; D027383:Papillomaviridae / Q000145:classification / Q000235:genetics / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000453:epidemiology* / Q000473:pathology / Q000821:virology; D016133:Polymerase Chain Reaction / Q000379:methods; D011237:Predictive Value of Tests; D013048:Specimen Handling / Q000379:methods; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology* / Q000473:pathology / Q000821:virology; D014626:Vaginal Smears; D002578:Uterine Cervical Dysplasia / Q000453:epidemiology* / Q000473:pathology / Q000821:virology
D004279:DNA, Viral